Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
Rhea-AI Summary
Zenas BioPharma (Nasdaq: ZBIO), a clinical-stage biopharmaceutical company focused on autoimmune disease therapies, has announced its upcoming participation in the Jefferies Global Healthcare Conference. The company's management will deliver a presentation on Thursday, June 5, 2025, at 1:25 p.m. ET. Interested parties can access both the live webcast and archived replay of the presentation through the "Events and Presentations" section of Zenas BioPharma's website under Investor & Media Relations.
Positive
- None.
Negative
- None.
News Market Reaction – ZBIO
In the trading session that priced this news, ZBIO gained 8.34%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced management’s presentation at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 1:25 p.m. ET.
A live webcast and archived replay of the Company’s presentation can be accessed under “Events and Presentations” in the Investor & Media Relations section of the Zenas BioPharma website.
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on LinkedIn.
The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.
Investor and Media Contact:
Argot Partners
Zenas@argotpartners.com
